BioPharma Resources

Drug Trial Radar · NCT07160244

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 6,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

6,000

Planned (sponsor's estimate)

Start

Aug 25, 2025

Primary completion

Nov 6, 2028

Study completion Mar 2, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 1 day, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

BEATRIX (group B strEptococcus mATeRnal and Infant VaX study) The purpose of this study is to learn about the safety and how the group B streptococcus (GBS) vaccine works in pregnant women and their babies. This study is seeking healthy pregnant participants: * aged 49 or younger who can join. * between 24 and 36 weeks of gestation ("Gestational age" is a medical term used to describe how far along your pregnancy is) * had a fetal ultrasound examination performed with no major fetal abnormalities observed * documented negative for HIV, syphilis and Hepatitis B All participants in this study will receive only 1 shot in an arm. This could either be a group B streptococcus 6-valent polysaccharide conjugate vaccine (GBS6) or placebo. Placebo is an inactive substance used in the study for comparison purposes; in this study, the placebo injection will be saline (saltwater). The pregnant participants may take part in this study for a maximum of 14 months (6 months after delivery) , and their babies for about 12 months after they are born. The pregnant participants will need to visit the research site at least 3 to 4 times with some visits permitted to occur over the telephone. A subset of infants will be asked to take part in the study for up to 19 months. The subset will receive diphtheria toxoid-containing vaccine and/or pneumococcal vaccine following each country's standard immunization plan and have blood drawn 1 month after completion of the primary and/or toddler (booster) doses.

Conditions

  • Healthy

Interventions

  • Multivalent Group B streptococcus vaccineBiological

    Multivalent Group B streptococcus vaccine

  • PlaceboBiological

    Saline Control

  • Infanrix hexaBiological

    Vaccine administered in a subset of infant participants as per the national immunization schedule

  • Prevenar 20Biological

    Vaccine administered in a subset of infant participants as per the national immunization schedule

  • PediarixBiological

    Vaccine administered in a subset of infant participants as per the national immunization schedule

  • Prevnar 20Biological

    Vaccine administered in a subset of infant participants as per the national immunization schedule

  • InfanrixBiological

    Vaccine administered in a subset of infant participants as per the national immunization schedule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of maternal participants reporting prespecified local reactions within 7 days following study interventionTime frame: Within 7 days
  2. The proportion of maternal participants reporting prespecified systemic events within 7 days following study interventionTime frame: Within 7 days
  3. The proportion of maternal participants reporting adverse events (AEs) through 1 month following study interventionTime frame: 1 month
  4. The proportion of maternal participants reporting serious adverse events (SAEs) through 6 months after deliveryTime frame: 6 months after delivery
  5. The proportion of maternal participants reporting medically attended adverse events (MAAEs) through 6 months after deliveryTime frame: 6 months after delivery
  6. The proportion of maternal participants reporting adverse events of special interest (AESIs) through 6 months after delivery.Time frame: 6 months after delivery
  7. The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting adverse events (AEs) from birth through 1 month of ageTime frame: Birth to 1 month of age
  8. The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting serious adverse events (SAEs) from birth through end of the studyTime frame: Through study completion, at least 1 year
  9. The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting medically attended adverse events (MAAEs) from birth through 6 months of ageTime frame: Birth to 6 months of age
  10. The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting adverse events of special interest (AESIs) from birth through end of studyTime frame: Through study completion, at least 1 year
  11. To measure the relative risk reduction in the proportion of infant participants at birth with GBS serotype-specific IgG antibody concentrations below predefined serotype-specific GBS late onset disease thresholds in the GBS6 group to the placebo groupTime frame: Birth
  12. To measure the relative risk reduction in the proportion of infant participants at birth with GBS serotype-specific IgG antibody concentrations below predefined serotype-specific GBS early onset disease thresholds in the GBS6 group to the placebo groupTime frame: Birth
  13. To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS late onset disease based on serotype specific anti-CPS IgG concentrations measured in infants at birth.Time frame: Birth
  14. To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS early onset disease based on serotype specific anti-CPS IgG concentrations measured in infants at birth.Time frame: Birth

Locations

219 sites in 15 countries. Site status is shown where the registry gives one.

  • Center for Research in Women's Health

    Birmingham, Alabama · Recruiting

  • Children's of Alabama

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham - School of Medicine

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham Women & Infants Center

    Birmingham, Alabama · Recruiting

  • SEC Clinical Research

    Dothan, Alabama · Recruiting

  • USA Health Allen Cox Building

    Mobile, Alabama · Recruiting

  • USA Health Children's and Women's Hospital

    Mobile, Alabama · Recruiting

  • USA Health Mitchell Cancer Institute

    Mobile, Alabama · Recruiting

  • USA Health Strada Patient Care Center

    Mobile, Alabama · Recruiting

  • ClinMed

    Phoenix, Arizona · Recruiting

  • Valleywise Comprehensive Health Center Women's Clinic

    Phoenix, Arizona · Recruiting

  • Valleywise Health Medical Center

    Phoenix, Arizona · Recruiting

  • Northwest Women's Center

    Tucson, Arizona · Recruiting

  • Genesis OB/GYN

    Tucson, Arizona · Recruiting

  • Eclipse Clinical Research

    Tucson, Arizona · Recruiting

  • Antelope Valley Medical Center

    Lancaster, California · Recruiting

  • Chemidox Clinical Trials

    Lancaster, California · Recruiting

  • Loma Linda University Children's Hospital

    Loma Linda, California · Recruiting

  • Loma Linda University Health System

    Loma Linda, California · Recruiting

  • Loma Linda University Pediatrics Clinic

    Loma Linda, California · Recruiting

  • Lucile Packard Children's Hospital

    Palo Alto, California · Recruiting

  • Stanford Obstetrics Clinic

    Palo Alto, California · Recruiting

  • Stanford University Medical Center

    Palo Alto, California · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • Anschutz Health Sciences Building

    Aurora, Colorado · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • CU Research Pharmacy

    Aurora, Colorado · Recruiting

  • University of Colorado AO1

    Aurora, Colorado · Recruiting

  • University of Colorado Hospital Outpatient Pavilion

    Aurora, Colorado · Recruiting

  • University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • University of Colorado Research II Building

    Aurora, Colorado · Recruiting

  • South Florida Clinical Research Institute - Margate

    Margate, Florida · Recruiting

  • Citadelle Clinical Research

    North Miami Beach, Florida · Recruiting

  • Emerald Coast OBGYN Clinical Research

    Panama City, Florida · Recruiting

  • Emerald Coast Pediatrics

    Panama City, Florida · Recruiting

  • HCA Florida Gulf Coast Hospital

    Panama City, Florida · Recruiting

  • ASR, LLC

    Boise, Idaho · Recruiting

  • Express Lab

    Garden City, Idaho · Recruiting

  • Clinical Research Prime

    Idaho Falls, Idaho · Recruiting

  • Eastern Idaho Regional Medical Center

    Idaho Falls, Idaho · Recruiting

Showing 40 of 219 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.